Results 21 to 30 of about 8,348 (154)
Frontiers in Cellular and Infection Microbiology, 2023 IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings.
José Ramón Santos +64 more
doaj +1 more source
PLoS ONE, 2019 Antiretroviral agents are approved in Japan based on non-clinical and clinical data reported from overseas. Neither the long-term tolerability nor the effectiveness of raltegravir or other integrase strand transfer inhibitors in Japan is known.
Naho Kuroishi +4 more
doaj +1 more source
Frontiers in Microbiology, 2019 The human immunodeficiency virus type 1 (HIV-1) has several proteins of therapeutic importance, many of which are currently used as drug targets in antiretroviral therapy. Among these proteins is the integrase, which is responsible for the integration of
Lucas de Almeida Machado +2 more
doaj +1 more source
Microbiology Spectrum, 2022 To ensure the long-term efficacy of dolutegravir (DTG), we evaluated the genotypic profile in viral reservoirs among patients on third-line (3L) antiretroviral therapy (ART) in Cameroon, according to prior exposure to raltegravir (RAL).
Joseph Fokam +31 more
doaj +1 more source
Direct Regioselective para‐Fluorination via I(I)/I(III) Catalysis
Angewandte Chemie International Edition, EarlyView.A direct, para‐selective fluorination by I(I)/I(III) catalysis is disclosed that does not require substrate pre‐functionalization. This strategy leverages the Leonard link inherent to phenylpropanoate and phenylpropanamides to promote a spirocyclization/para‐selective sequence. The C3‐side chain maps onto a range of common drug scaffolds and allows the
Christoph Roblick +5 more
wiley +1 more source
Frontiers in Pharmacology, 2019 Background: The life expectancy for HIV-infected individuals has improved dramatically because of improvements in antiretroviral therapy (ART). Today, a simplified two-drug regimen enhances adherence and treatment satisfaction by reducing adverse effects.
Yinqiu Huang +6 more
doaj +1 more source
Features of application of raltegravir in HIV-infected patients with different somatic pathologies
Журнал инфектологии, 2021 Purpose of the study. Evaluation of the efficacy, safety and tolerability of raltegravir regimens in HIV-infected patients with concomitant pathology in real clinical practice.Materials and methods.
N. V. Sizova +2 more
doaj +1 more source
Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications
British Journal of Clinical Pharmacology, EarlyView.Dolutegravir underpins modern first‐ and second‐line HIV treatment regimens; however, interindividual variability in its disposition and tolerability presents challenges for optimal use. This scoping review mapped current evidence on the pharmacogenomics of dolutegravir, focusing on pharmacokinetics and pharmacodynamics, and methodological limitations ...
Ronald Kiguba +2 more
wiley +1 more source
Acta Obstetricia et Gynecologica Scandinavica, EarlyView.In women living with HIV, HPV clearance occurred after a mean of approximately 2 years under antiretroviral therapy. Baseline positivity for the high‐risk HPV pool was associated with delayed clearance, suggesting that HPV genotype may influence viral persistence more than immunovirological status in clinically stable patients.
Annunziata Carlea +10 more
wiley +1 more source
Journal of Virus Eradication, 2015 Background: It is unclear whether intensification of standard highly active antiretroviral therapy (HAART) with entry and integrase inhibitors during acute HIV infection (AHI) could yield greater benefits in reducing markers for HIV reservoir size and ...
Jintanat Ananworanich +16 more
doaj +1 more source